Otulana acquired 25,000 shares at a price of 38.8 US cents each, and now holds 50,000 shares.
Allergy Therapeutics closed up 0.7% to
Fri, 16th Mar 2018 17:30
Otulana acquired 25,000 shares at a price of 38.8 US cents each, and now holds 50,000 shares.
Allergy Therapeutics closed up 0.7% to
Allergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says it continued to work on initiatives to improve cost control and manage working capital alongside trading broadly in line with expectations for the current financial year to date. Says it has extended its cash runway and anticipates to require additional funding by the end of December. Further, says discussions with some major shareholders regarding a subscription and open offer announced in October have progressed. Says that the pivotal phase 3 grass G306 modified allergen tyrosine adsorbed monophosphoryl lipid A trial remains on track to report interim results this month. Via G306, the company aims to release an immunotherapy for grass allergy.
Read more(Alliance News) - ZQ Capital Management Ltd on Monday announced a mandatory takeover offer for Allergy Therapeutics PLC, as required under UK takeover rules, but it said the offer won't be accepted by the Allergy's second largest shareholder and so won't succeed.
Read moreAllergy Therapeutics PLC - West Sussex, England-based commercial biotechnology company - Says that it has conditionally raised total gross proceeds of approximately GBP40.8 million through an equity financing, which was announced on April 6. Proceeds of the equity financing will be used to repay amounts owed under the loan facility agreement.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday, Thursday and Wednesday and not separately reported by Alliance News:
Read more(Alliance News) - Allergy Therapeutics PLC on Thursday said it expects to swing to a loss for the full-year as revenue plummets on production disruptions.
Read more(Alliance News) - Allergy Therapeutics PLC on Monday said it has promoted Group Financial Controller Shaun Furlong to chief financial officer.
Read more(Alliance News) - Allergy Therapeutics PLC on Monday said its loss widened and revenue fell, with costs going up as new research studies progress, but predicted improved sales in the second half of the year thanks to higher demand in the seasonal allergy market.
Read more(Alliance News) - Allergy Therapeutics PLC on Thursday said it has entered into a senior secured facility agreement with ZQ Capital Management Ltd, through its affiliate SkyGem International Holdings Ltd and Southern Fox Investments Ltd.
Read more(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
Read more(Sharecast News) - Allergy Therapeutics, a UK-based biotechnology company specialising in allergy vaccines, announced the start of the first application of its 'VLP Peanut' vaccine candidate in peanut-allergic patients on Monday.
Read more(Sharecast News) - Commercial biotechnology company Allergy Therapeutics said in an update on Friday that it expects first-half revenue of £39.9m, making for a decrease of 18% year-on-year.
Read more(Alliance News) - Allergy Therapeutics PLC on Friday said it expects a drop in revenue during the first half of its financial year, but it remains confident about funding opportunities.
Read more(Alliance News) - London's FTSE 100 achieved a solid, though unspectacular, gain during the final full trading of the year on Thursday, with investors mindful of what an ease of Covid-19 curbs in China could mean for global inflation.
Read more